Device-Detected Atrial Fibrillation.
暂无分享,去创建一个
I. V. Van Gelder | M. Rienstra | Michiel Rienstra | Isabelle C Van Gelder | B. Mulder | Bart A Mulder
[1] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[2] Panos Vardas,et al. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial , 2017, American heart journal.
[3] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[4] Joel Stein,et al. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.
[5] Mintu P Turakhia,et al. Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation. , 2019, Circulation.
[6] Giuseppe Boriani,et al. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. , 2017, Heart rhythm.
[7] Marco Proietti,et al. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. , 2015, International journal of cardiology.
[8] A. Capucci,et al. Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.
[9] Dongfeng Qi,et al. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study , 2009, Circulation. Arrhythmia and electrophysiology.
[10] Philippe Mabo,et al. Rationale and design of the Apixaban for the Reduction of Thrombo‐Embolism in Patients With Device‐Detected Sub‐Clinical Atrial Fibrillation (ARTESiA) trial , 2017, American heart journal.
[11] U. Schotten,et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation , 2017, European heart journal.
[12] Hugh Calkins,et al. Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Circulation.
[13] G. Breithardt,et al. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[14] Kenneth A Ellenbogen,et al. Device-detected atrial fibrillation: what to do with asymptomatic patients? , 2015, Journal of the American College of Cardiology.